Open AccessHigher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease
Author(s) -
Ryan C. Ungaro,
Andrés Yarur,
Jacqueline Jossen,
Becky L. Phan,
Ezra Chefitz,
Priya Sehgal,
Kanika Kamal,
Alexandra Bruss,
Poonam Beniwal-Patel,
Caroline S. Fox,
Amir Patel,
Bayda Bahur,
Anjali Jain,
Daniel J. Stein,
Snehal Naik,
Marla Dubinsky
Publication year - 2019
Publication title -
journal of crohn's and colitis
Language(s) - English
Resource type - Journals
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1093/ecco-jcc/jjz041
Subject(s) - vedolizumab , medicine , ulcerative colitis , gastroenterology , inflammatory bowel disease , maintenance therapy , corticosteroid , therapeutic drug monitoring , trough level , disease , chemotherapy , pharmacokinetics , transplantation , tacrolimus
Vedolizumab is an anti-α4β7 biologic approved for ulcerative colitis [UC] and Crohn's disease [CD]. We aimed to examine the association of maintenance vedolizumab concentrations with remission.